The evidence supporting therapy with imatinib for bleomycin-induced pneumonitis (BIP) is equivocal. Further experience is needed to establish its role in BIP management. While it may be considered in the management of BIP, it is important to be mindful of the adverse effects including thrombocytopenia and gastrointestinal bleeding.
Keywords: Bleomycin; imatinib mesylate; intensive care; pulmonary toxicity; respiratory failure; treatment outcome.